Clinical Trials
4 trialsNCT02186821 2021-04-08
SIGNATURE
Novartis
Phase 2 Terminated
NCT01742286 2020-06-09
Phase I Study of LDK378 in Pediatric, Malignancies With a Genetic Alteration in Anaplastic Lymphoma Kinase (ALK)
Novartis
Phase 1 Completed
NCT02465528 2019-12-27
Ceritinib Rare Indications Study in ALK+ Tumors
Novartis
Phase 2 Terminated
NCT02729961 2019-10-10
Ceritinib With Brentuximab Vedotin in Treating Patients With ALK-Positive Anaplastic Large Cell Lymphoma
University of Washington
Phase 1/2 Withdrawn